Guselkumab Significantly Improves Disease Activity in PsA Over 100 Weeks
HCP Live,
Laura C Coates, MBChB, MRCP, PhD Credit: University of Oxford A substantial proportion of patients with psoriatic arthritis (PsA…
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized…
Overview of attention for article published in BMC Rheumatology, February 2024
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Among the highest-scoring outputs from this source (#42 of 256)
-
High Attention Score compared to outputs of the same age (90th percentile)
Readers on
- mendeley
- 21 Mendeley
